Sign in to view content

ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: Phase 1 OPTIC Trial Update

Dante Joseph Pieramici, MD

Video
Published 2022

Related

Intravitreal Gene Therapy for Neovascular AMD with ADVM-022: Results of the Phase 1 OPTIC Trial
Dante Joseph Pieramici, MD
Annual Meeting Talks
2021
Impact of Duration of Exposure to Residual Intraretinal Fluid on Visual Function Outcomes in Neovascular Age-Related Macular Degeneration (nAMD)
Nathan C. Steinle, MD
On Demand Cases, Courses, and Papers
2021
Endophthalmitis After Intravitreal Injections with 0.05% Aqueous Chlorhexidine vs 5% Povidone-Iodine as Ocular Antiseptics
Murtaza K Adam, MD
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more